Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083889 · ClinicalTrials.gov registry record · Phase 3
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
A Phase 3 study of Carcinoma, Renal Cell, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT00083889: Completed Phase 3 study of Carcinoma, Renal Cell, sponsored by Pfizer.
NCT00083889 is a Phase 3 study of Carcinoma, Renal Cell that has completed, run by Pfizer. The registered enrollment target is 750 participants, above the 261-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (187% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083889, a Phase 3 study of Carcinoma, Renal Cell, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
Primary Outcome
Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.
Conditions Studied
Interventions
- DRUG SU011248
- DRUG Interferon-alfa
Study Locations (20)
California
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Francisco
Connecticut
- Pfizer Investigational Site - New Haven
- Pfizer Investigational Site - New Haven
- Pfizer Investigational Site - New Haven
Florida
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Tampa
Illinois
- Pfizer Investigational Site - Chicago
- Pfizer Investigational Site - Maywood
Kansas
- Pfizer Investigational Site - Kansas City
- Pfizer Investigational Site - Overland Park
Louisiana
- Pfizer Investigational Site - Covington
- Pfizer Investigational Site - Metairie
Arkansas
- Pfizer Investigational Site - Jonesboro
Colorado
- Pfizer Investigational Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2004-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00083889 record still lists
NCT00083889 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 261-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (187% higher).
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 2 interventions - of which SU011248 is the first listed.
NCT00083889 names 20 study sites across 9 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00083889 about?
NCT00083889 is a clinical study titled "SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma". The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
What is the current status of trial NCT00083889?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2004-08. Estimated completion is 2008-09.
What conditions does trial NCT00083889 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00083889?
The interventions under investigation include: SU011248 (DRUG), Interferon-alfa (DRUG).
Who is sponsoring clinical trial NCT00083889?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083889 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00083889's enrollment target sits among peer trials
750 5th of 34 higher than 30 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Savolitinib vs. Sunitinib in MET-driven PRCC.
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia